Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants
Yoshitomo Morinaga, Hideki Tani, Yasushi Terasaki, Satoshi Nomura, Hitoshi Kawasuji, Takahisa Shimada, Emiko Igarashi, Yumiko Saga, Yoshihiro Yoshida, Rei Yasukochi, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Takashi Fujimura, Yoichi Ishida, Kazunori Oishi, Yoshihiro Yamamoto
Abstract
This study provides a diagnostic evidence of test validity, which can lead to vaccine efficacy and proof of recovery after COVID-19. It is not easy to know neutralization against SARS-CoV-2 in the clinical laboratory because of technical and biohazard issues. The correlation of the quantitative anti-receptor-binding domain antibody test, which is widely available, with neutralizing test indicates that we can know indirectly the state of acquisition of functional immunity against wild and variant-type viruses in the clinical laboratory.